NASDAQ:PRVL Prevail Therapeutics (PRVL) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free PRVL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$23.00▼$23.0050-Day Range$22.91▼$23.2052-Week Range$9.02▼$23.35VolumeN/AAverage Volume955,800 shsMarket Capitalization$787.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Prevail Therapeutics alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About Prevail Therapeutics Stock (NASDAQ:PRVL)Prevail Therapeutics Inc., a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases. The company's lead product candidate is PR001, which is in Phase I/II clinical trial for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease. It is also developing PR006 for the treatment of frontotemporal dementia with GRN mutation; and PR004 for the treatment of synucleinopathies. Prevail Therapeutics Inc. was founded in 2017 and is based in New York, New York.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. PRVL Stock News HeadlinesMarch 6, 2024 | msn.comHalestorm Announce Co-Headlining Tour in 2024 with I PrevailMarch 4, 2024 | msn.comHalestorm + I Prevail Announce 2024 North American Summer TourMarch 28, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. February 5, 2024 | uk.movies.yahoo.comLori Kay Relaunches Management & Production Company Prevail Artist EntertainmentNovember 2, 2023 | yahoo.comPrimates Prevail in Teaser for Kingdom of the Planet of the Apes: WatchOctober 28, 2023 | ft.comHumanity must prevail in GazaOctober 24, 2023 | msn.comInsane Airflow, Impressively Durable: Specialized S-Works Prevail 3 Bike Helmet 1-Year ReviewOctober 12, 2023 | msn.comPrevail Bank in Wausau helping community growMarch 28, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.September 18, 2023 | finance.yahoo.comHemogenyx Pharmaceuticals PLC Announces Strategic Investment from Prevail Partners, LLCJuly 25, 2023 | msn.comSpecialized/Fjallraven Prevail Helmet review: summery lid for bikepackingJuly 18, 2023 | msn.comHard rock band Godsmack, with I Prevail, will play the Resch Center in SeptemberMay 19, 2023 | benzinga.comBriaCell Closes $4 Million Strategic Investment by Prevail Partners, LLC at US$8.63 per ShareMay 9, 2023 | usnews.comNorth Korea's Kim Says Russia 'Will Prevail' Over Hostile ForcesMarch 26, 2023 | abcnews.go.comAbortion-rights supporters prevail in New Hampshire HouseFebruary 1, 2023 | msn.comNovartis Ag (NVS) Q4 2022 Earnings Call TranscriptJanuary 5, 2023 | forbes.comWhy Some Teams Fail And Others PrevailJanuary 5, 2023 | msn.comDelhi Wakes Up To Chilling 3 Degrees, Season’s Lowest; Coldwave, Fog To Prevail In These States | Full ForecastNovember 21, 2022 | msn.comPrevail Bank makes donation to local teen homeless shelterNovember 2, 2022 | seekingalpha.comVanda Pharmaceuticals Inc. (VNDA) Q3 2022 Earnings Call TranscriptNovember 1, 2022 | msn.comPrevail Bank Eau Claire branch grand reopeningSeptember 24, 2022 | news.yahoo.com5 things to know from I Prevail's 'True Power' Tour stop in LubbockSeptember 9, 2022 | yahoo.comI Prevail Reflect on the Pandemic, ‘Trauma’ and New LP ‘True Power’August 4, 2022 | msn.comPrevail Bank donates funds for school supply driveAugust 3, 2022 | usnews.comTrump-Backed Candidates Prevail, While Kansas Votes to Preserve Abortion RightsJune 17, 2022 | yahoo.comI Prevail Announce New Album True Power, Unveil New Song “Body Bag”: StreamJune 11, 2022 | usnews.comZelenskiy Says Ukraine Is 'Definitely Going to Prevail in This War'See More Headlines Receive PRVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prevail Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/13/2020Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:PRVL CUSIPN/A CIKN/A Webwww.prevailtherapeutics.com Phone917-336-9310FaxN/AEmployees66Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-63,190,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.57% Return on Assets-48.14% Debt Debt-to-Equity RatioN/A Current Ratio7.56 Quick Ratio7.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book4.74Miscellaneous Outstanding Shares34,246,000Free FloatN/AMarket Cap$787.66 million OptionableNot Optionable Beta1.59 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Asa Abeliovich M.D. (Age 56)Ph.D., Founder, Pres, CEO & Director Comp: $737.47kDr. Yong Dai Ph.D. (Age 49)Chief Technology Officer Comp: $450.62kDr. Jeffrey Sevigny M.D. (Age 51)Chief Medical Officer Comp: $593kDr. Brett Kaplan M.D. (Age 46)CFO & Sec. Ms. Kira M. SchwartzGen. CounselMs. Emily Minkow (Age 37)Chief Bus. Officer Dr. Franz F. Hefti Ph.D. (Age 72)Chief Devel. Officer More ExecutivesKey CompetitorsHilleVaxNASDAQ:HLVXPrime MedicineNYSE:PRMECabaletta BioNASDAQ:CABAAllogene TherapeuticsNASDAQ:ALLOCullinan OncologyNASDAQ:CGEMView All Competitors PRVL Stock Analysis - Frequently Asked Questions How were Prevail Therapeutics' earnings last quarter? Prevail Therapeutics Inc. (NASDAQ:PRVL) released its earnings results on Friday, November, 13th. The company reported ($0.55) earnings per share for the quarter, beating analysts' consensus estimates of ($0.64) by $0.09. What other stocks do shareholders of Prevail Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Prevail Therapeutics investors own include Sorrento Therapeutics (SRNE), Alector (ALEC), Gossamer Bio (GOSS), Editas Medicine (EDIT), Harpoon Therapeutics (HARP), Atreca (BCEL), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO) and Stoke Therapeutics (STOK). When did Prevail Therapeutics IPO? Prevail Therapeutics (PRVL) raised $126 million in an IPO on Thursday, June 20th 2019. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company served as the underwriters for the IPO and Wedbush PacGrow was co-manager. This page (NASDAQ:PRVL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prevail Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.